Introduction  The prognosis of oesophageal cancer remains poor with < 10% 5-year survival. Delineating the molecular pathogenesis of oesophageal cancer could inform future research into targeted therapies and may uncover novel biomarkers to aid management decisions. As a transcription factor with important roles in the control of cell cycle transcription, FOXM1 regulates cellular proliferation and chromosome stability. FOXM1 is frequently overexpressed in human cancers and this aberrant expression has been implicated in cancer initiation, progression and resistance to chemotherapy. Overexpression of FOXM1 mRNA and protein has recently been described in oesophageal adenocarcinoma (OAC) tissues. We aim to identify novel gene targets of FOXM1 to better understand the molecular pathogenesis of OAC.

Methods  Chromatin immunoprecipitation (ChiP) followed by deep sequencing (ChiP-seq) of FOXM1 binding sites was performed in OE33 OAC cells. FOXM1 binding at target gene promoters was confirmed with ChiP-qPCR studies. Target gene expression in OE33 cells after siRNA-mediated FOXM1 depletion was examined using qRT-PCR and western blotting. Target gene expression in OAC tissues was examined by analysis of microarray gene expression data. Statistical significance (p) in knockdown studies was calculated by Student’s t-test. The Pearson correlation coefficient (r) was used to measure strength of correlation of gene expression.

Results  Putative novel FOXM1 targets identified from an existing FOXM1 ChiP-seq dataset in U2OS osteosarcoma cells were validated by ChiP-seq in OE33 cells. A large overlap between the genes bound by FOXM1 in both cell types was observed. Genes with FOXM1 binding in both cell types whose expression was highly correlated with FOXM1 in OAC tissues such as ETV4, SKA2 and NUCKS1 (r = 0.85, 0.84 and 0.72) were analysed further with ChiP-qPCR and FOXM1 knockdown gene expression studies. OE33 cells demonstrated significant FOXM1 binding at the ETV4 promoter and a reduction in ETV4 mRNA in FOXM1 depleted cells was observed compared to control (p = 0.0006). However, despite highly significant FOXM1 binding at the SKA2 and NUCKS1 promoters the reduction in SKA2/NUCKS1 mRNA following FOXM1 knockdown was modest and not significant.

Conclusion  We have identified ETV4 as a novel FOXM1 target in oesophageal cancer. We found strong correlation with FOXM1 expression in clinical tissues, in vitro FOXM1 binding to its regulatory regions and evidence of regulation by FOXM1 in OE33 cells. Our studies also highlight the importance of validating ChiP-seq data with gene expression analysis since transcription factor binding at gene promoters does not always correlate with transcriptional regulation by that transcription factor.

Disclosure of Interest  None Declared

NGM free papers

OC-032  A NEW VALIDATED WHOLE GUT TRANSIT TIME (WGTT) MEASUREMENT USING MAGNETIC RESONANCE IMAGING (MRI-WGTT) TECHNIQUE

doi:10.1136/gutjnl-2013-304907.032

1 C Lam, 2 G Chaddock, 2 C Hoad, 2 C Costigan, 2 E Cox, 1 L Marciani, 2 P Gowland, 1 R Spiller. 1 NIHR Nottingham Digestive Diseases Biomedical Research Unit; 2 Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, Nottingham, UK

Introduction  Disorders of gut transit are very common in gastroenterology clinics. Objective assessment may be useful for targeting and monitoring treatment. Current scintigraphic or radio-opaque marker techniques involve undesirable ionising radiation.

Aims

1. To validate a new MRI method for measuring WGTT against the current gold standard in which 20 radio-opaque markers (ROMs) are ingested per day on 3 consecutive days and the number retained assessed from a single abdominal x-ray on day 4.

2. To assess reproducibility of MRI-WGTT.

Methods  20 healthy volunteers (HV) ages 21–70 (12 males and 8 females) participated in the study involving 2 visits a week apart (test-retest). On each visit, each HV underwent 2 tests: (A) MRI-WGTT test for which HV swallow 5 pills, each filled with a MRI contrast agent diluted with water, 24 hours before undergoing MRI scans which precisely locate the pills in the colon. Transit of the markers was assessed by scoring each pill from its position in the colon (7 = small bowel, 6 = lower ascending, 5 = upper AC, 4 = right transverse (TC), 3 = left TC, 2 = descending, 1 = rectosigmoid, 0 = expelled) and calculating an average score (Transit score TS) using an algorithm which gives a weighting inversely related to the distance from the median. (B) ROM test: the number of ROM was counted and multiplied by 1.2 to give a WGTT in hours. Spearman’s correlation was used to assess the correlation between the two measurements and intra-class correlation coefficient (ICC) was used to assess the variability of each test when repeated twice.

Results  The MRI images provided excellent 3D spatial resolution, allowing the gut to be viewed from all angles, hence allowing accurate location of the pills within the colon especially the sigmoid region (Figure 1). WGTT using ROM was median (SD), 27.6 (20.8) and TS was 0.9 (0.8). WGTT using ROM and TS were well correlated, Spearman’s r = 0.85, p < 0.01. Using this we converted TS to MRI-WGTT in hours. Mean calculated MRI-WGTT was 27.6 (24.7) hours. The mean absolute difference in the MRI-WGTT on 2 separate visits was 15.3 hours (SD, 15.8) with an ICC of 0.62 (p < 0.01). The mean absolute difference in the WGTT for ROMs on 2 separate visits was 11.5 hours (SD, 9.7) with and ICC of 0.69 (p < 0.01).

Conclusion  MRI-WGTT correlated well with the gold standard ROM WGTT but was more convenient, involving only one day of marker ingestion and no exposure to ionising radiation. This technique could be implemented easily in most NHS hospitals. Funded by: Medical Research Council and NIHR UK.

Disclosure of Interest  None Declared

OC-033  IS LYMPHOCYTIC DUODENOSIS A MARKER FOR IRRITABLE BOWEL SYNDROME?

doi:10.1136/gutjnl-2013-304907.033

1 I Aziz, 1 D M Smille, 1 D S Sanders. 1 Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK

Introduction  In a previous study we demonstrated a significant increase in the prevalence of Lymphocytic Duodenitis in patients with Irritable Bowel Syndrome (IBS) compared to healthy volunteers. This study has limitations due to the small number of patients studied and the cross-sectional nature of the design.
**CORTICAL AND BRAINSTEM NEUROPHYSIOLOGICAL MECHANISMS UNDERLYING DYSPHAGIA IN PARKINSON’S DISEASE: A TRANSCRANIAL MAGNETIC STIMULATION STUDY ‘ON’ AND ‘OFF’ LEVODOPA**

doi:10.1136/gutjnl-2013-304907.034

1E Michou, 1L Harris, 1,*S Hamdy. 1Gastrointestinal Sciences, University of Manchester, Manchester, UK

**Introduction**

Dysphagia in Parkinson’s disease (PD) patients, persisting despite dopaminergic medication, affects nutritional and drug intake with reduced quality-of-life (Michou & Hamdy, Exp Rev Neurother 2010). Here we explore the potential neurophysiological mechanisms underlying dysphagia in PD when ‘on’ and ‘off’ Levodopa with transcranial magnetic stimulation (TMS).

**Methods**

26 verified PD patients (65 ± 8 yoa, 10 male) completed the Swallowing Disturbance Questionnaire (Manor et al Mov Dis 2007) and SWAL-QOL (McHorney et al Dysphagia 2002). After 12 hours ‘off’ L-dopa, patients underwent a) cortical TMS mapping for pharyngeal musculature, b) brainstem reflexes TMS stimulation, c) lung function tests with spirometry before and after (d) videofluoroscopy (VFS) of liquid, pureed boluses and saliva. These were repeated following the administration of L-dopa to the patients. Factorial and non-parametric statistical tests were applied.

**Results**

VFS identified dysphagia in 10 patients (Group A), while 6 patients showed swallowing difficulties only ‘On-L-dopa’ (Group B), with the remainder 10 subjects being non-dysphagic (Group C).

Swal-QOL score was reduced in Group A (p < 0.05), while aspiration-penetration scores (thin and puree consistencies) and additional ‘clearing swallows’ worsened after administration of L-dopa (p < 0.05) for Group B. After Levodopa intake, cortical pharyngeal excitability was decreased significantly in Group A (p < 0.001), but increased in Group C (p < 0.001) compared to ‘off-state’ (Figure 1).

No significant change in lung function was observed during the off-or on-state, nor did lung function correlate with dysphagia. The amplitudes of the brainstem reflexes were different between the 3 groups ‘on-Levodopa’.

**Conclusion**

17% of LD is associated with the Rome III criteria for IBS. LD may, therefore, be a disease marker for IBS and a reflection of low grade inflammatory response although no clues to the triggering mechanism were elucidated.

**Disclosure of Interest**

None Declared

---

**LYMPHOCYTIC DUODENOSIS (LD) AND IRRITABLE BOWEL SYNDROME (IBS)**

**Aims**

To prospectively assess the associations between LD and IBS.

**Methods**

Two hundred patients with LD were investigated for associated LD conditions, by means of revisiting the patient’s history and recent investigations including the initial coeliac serology, followed by a combination of gluten challenge, HLA typing, repeat duodenal biopsies, and exclusion of infection/inflammatory bowel disease.

A diagnosis of CD was based on the persistence or progression of LD on a gluten-containing diet, the presence of HLA DQ2 or DQ8, and a clinical response to a gluten free diet.

In the absence of an alternative cause, a diagnosis of IBS was made on the presence of the Rome III criteria.

**Results**

150 female, 50 male, mean age 49, SD 16, age range 17–83

An identifiable association was found in 70% of patients : CD (20%), NSAIDs (17%) and H. pylori (16%) accounting for the majority. Other causes included gastrointestinal infections (7%), autoimmune disorders (5.5%), inflammatory bowel disease (2%), TB or HIV (1.5%), and IgA deficiency (1%).

In 60 cases (30%) no cause was found, although reassuringly two-thirds normalised their histology. In just over half of those without an identifiable cause, symptoms were consistent with IBS (35/60). IBS, therefore, accounted for 17% of all LD cases.

Whereas all patients with CD were HLA positive, only 55% of those with alternative causes or IBS were HLA positive (p < 0.0001).

**Conclusion**

17% of LD is associated with the Rome III criteria for IBS. LD may, therefore, be a disease marker for IBS and a reflection of low grade inflammatory response although no clues to the triggering mechanism were elucidated.

**Disclosure of Interest**

None Declared

---

Abstract OC-034 Figure 1